Talking Euretina Whipsmart Media

In this podcast, Prof Frank Holz (Germany) discusses assessment of visual dysfunction in Intermediate AMD in the context of the Macustar trial with Dr Hannah Dunbar, Principal Optometrist at Moorfields and UCL

In this podcast, Bart Leroy and Mark Pennesi discuss a provocative paper in Cell that seems to draw a link between bacteria normally found in our gut and retinal diseases such as Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). This episode was an initiative of EURETINA in collaboration with ERN-EYE (European Reference Network for Rare Eye Disease). 

In this episode, Zohar Habot-Wilner (Israel) and Elisabetta Miserocchi (Italy) explore the key elements of clinical examination and how to approach work up when treating patients presenting with Uveitis. The discussion is chaired by Bahram Bodhagi (France)

In this episode, something a little different from the world of basic science: an interview with Bob J Johnston of Johns Hopkins who has been working with retinal organoids for the past decade. How are they made? What does industry think of them and will they one day become the default paradigm for retinal clinical research? Chaired by Jonathan McCrea

In this episode, we hear from an expert panel as they delve into the critical topic of second eye risk of retinal detachment (RD) and discuss approaches to prophylaxis. With Alistair Laidlaw (UK), Patricia Udaondo (Spain) and David Steel (UK)

Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes